Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Jun;80(7):981–990. doi: 10.1038/sj.bjc.6690452

Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines

C J A van Moorsel 1, H M Pinedo 1, G Veerman 1, A M Bergman 1, C M Kuiper 1, J B Vermorken 1,1, W J F van der Vijgh, G J Peters 1
PMCID: PMC2363050  PMID: 10362105

Abstract

2′,2′-Difluorodeoxycytidine (gemcitabine, dFdC) and cis-diammine-dichloroplatinum (cisplatin, CDDP) are active agents against ovarian cancer and non-small-cell lung cancer (NSCLC). CDDP acts by formation of platinum (Pt)–DNA adducts; dFdC by dFdCTP incorporation into DNA, subsequently leading to inhibition of exonuclease and DNA repair. Previously, synergism between both compounds was found in several human and murine cancer cell lines when cells were treated with these drugs in a constant ratio. In the present study we used different combinations of both drugs (one drug at its IC25 and the other in a concentration range) in the human ovarian cancer cell line A2780, its CDDP-resistant variant ADDP, its dFdC-resistant variant AG6000 and two NSCLC cell lines, H322 (human) and Lewis lung (LL) (murine). Cells were exposed for 4, 24 and 72 h with a total culture time of 96 h, and possible synergism was evaluated by median drug effect analysis by calculating a combination index (CI; CI < 1 indicates synergism). With CDDP at its IC25, the average CIs calculated at the IC50, IC75 IC90 and IC95 after 4, 24 and 72 h of exposure were < 1 for all cell lines, indicating synergism, except for the CI after 4 h exposure in the LL cell line which showed an additive effect. With dFdC at its IC25, the CIs for the combination with CDDP after 24 h were < 1 in all cell lines, except for the Cls after 4 h exposure in the LL and H322 cell lines which showed an additive effect. At 72 h exposure all Cls were < 1. CDDP did not significantly affect dFdCTP accumulation in all cell lines. CDDP increased dFdC incorporation into both DNA and RNA of the A2780 cell lines 33- and 79-fold (P < 0.01) respectively, and tended to increase the dFdC incorporation into RNA in all cell lines. In the AG6000 and LL cell lines, CDDP and dFdC induced > 25% more DNA strand breaks (DSB) than each drug alone; however, in the other cell lines no effect, or even a decrease in DSB, was observed. dFdC increased the cellular Pt accumulation after 24 h incubation only in the ADDP cell line. However, dFdC did enhance the Pt–DNA adduct formation in the A2780, AG6000, ADDP and LL cell lines (1.6-, 1.4-, 2.9- and 1.6-fold respectively). This increase in Pt–DNA adduct formation seems to be related to the incorporation of dFdC into DNA (r = 0.91). No increase in DNA platination was found in the H322 cell line. dFdC only increased Pt–DNA adduct retention in the A2780 and LL cell lines, but decreased the Pt–DNA adduct retention in the AG6000 cell line. In conclusion, the synergism between dFdC and CDDP appears to be mainly due to an increase in Pt–DNA adduct formation possibly related to changes in DNA due to dFdC incorporation into DNA. © 1999 Cancer Research Campaign

Keywords: cisplatin, gemcitabine, DNA damage, strand breaks, DNA adducts

Full Text

The Full Text of this article is available as a PDF (168.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbruzzese J. L., Frost P. Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin. Cancer Chemother Pharmacol. 1992;30(1):31–36. doi: 10.1007/BF00686482. [DOI] [PubMed] [Google Scholar]
  2. Abbruzzese J. L., Grunewald R., Weeks E. A., Gravel D., Adams T., Nowak B., Mineishi S., Tarassoff P., Satterlee W., Raber M. N. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991 Mar;9(3):491–498. doi: 10.1200/JCO.1991.9.3.491. [DOI] [PubMed] [Google Scholar]
  3. Abratt R. P., Bezwoda W. R., Goedhals L., Hacking D. J. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol. 1997 Feb;15(2):744–749. doi: 10.1200/JCO.1997.15.2.744. [DOI] [PubMed] [Google Scholar]
  4. Bergman A. M., Ruiz van Haperen V. W., Veerman G., Kuiper C. M., Peters G. J. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res. 1996 Mar;2(3):521–530. [PubMed] [Google Scholar]
  5. Birnboim H. C., Jevcak J. J. Fluorometric method for rapid detection of DNA strand breaks in human white blood cells produced by low doses of radiation. Cancer Res. 1981 May;41(5):1889–1892. [PubMed] [Google Scholar]
  6. Chiu C. S., Chan A. K., Wright J. A. Inhibition of mammalian ribonucleotide reductase by cis-diamminedichloroplatinum(II). Biochem Cell Biol. 1992 Dec;70(12):1332–1338. doi: 10.1139/o92-181. [DOI] [PubMed] [Google Scholar]
  7. Chou T. C., Motzer R. J., Tong Y., Bosl G. J. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst. 1994 Oct 19;86(20):1517–1524. doi: 10.1093/jnci/86.20.1517. [DOI] [PubMed] [Google Scholar]
  8. Crinò L., Scagliotti G., Marangolo M., Figoli F., Clerici M., De Marinis F., Salvati F., Cruciani G., Dogliotti L., Pucci F. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 1997 Jan;15(1):297–303. doi: 10.1200/JCO.1997.15.1.297. [DOI] [PubMed] [Google Scholar]
  9. Ellerhorst J. A., Frost P., Abbruzzese J. L., Newman R. A., Chernajovsky Y. 2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation. Br J Cancer. 1993 Feb;67(2):209–215. doi: 10.1038/bjc.1993.41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Freeman K. B., Anliker S., Hamilton M., Osborne D., Dhahir P. H., Nelson R., Allerheiligen S. R. Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Appl. 1995 Mar 10;665(1):171–181. doi: 10.1016/0378-4347(94)00521-6. [DOI] [PubMed] [Google Scholar]
  11. Heinemann V., Hertel L. W., Grindey G. B., Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1988 Jul 15;48(14):4024–4031. [PubMed] [Google Scholar]
  12. Huang P., Chubb S., Hertel L. W., Grindey G. B., Plunkett W. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991 Nov 15;51(22):6110–6117. [PubMed] [Google Scholar]
  13. Lu Y., Han J., Scanlon K. J. Biochemical and molecular properties of cisplatin-resistant A2780 cells grown in folinic acid. J Biol Chem. 1988 Apr 5;263(10):4891–4894. [PubMed] [Google Scholar]
  14. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst. 1991 Jun 5;83(11):757–766. doi: 10.1093/jnci/83.11.757. [DOI] [PubMed] [Google Scholar]
  15. Parker R. J., Gill I., Tarone R., Vionnet J. A., Grunberg S., Muggia F. M., Reed E. Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis. 1991 Jul;12(7):1253–1258. doi: 10.1093/carcin/12.7.1253. [DOI] [PubMed] [Google Scholar]
  16. Peters G. J., Laurensse E., Leyva A., Pinedo H. M. Purine nucleosides as cell-specific modulators of 5-fluorouracil metabolism and cytotoxicity. Eur J Cancer Clin Oncol. 1987 Dec;23(12):1869–1881. doi: 10.1016/0277-5379(87)90053-8. [DOI] [PubMed] [Google Scholar]
  17. Peters G. J., Schornagel J. H., Milano G. A. Clinical pharmacokinetics of anti-metabolites. Cancer Surv. 1993;17:123–156. [PubMed] [Google Scholar]
  18. Peters G. J., Wets M., Keepers Y. P., Oskam R., van Ark-Otte J., Noordhuis P., Smid K., Pinedo H. M. Transformation of mouse fibroblasts with the oncogenes H-ras OR trk is associated with pronounced changes in drug sensitivity and metabolism. Int J Cancer. 1993 May 28;54(3):450–455. doi: 10.1002/ijc.2910540316. [DOI] [PubMed] [Google Scholar]
  19. Ruiz van Haperen V. W., Veerman G., Boven E., Noordhuis P., Vermorken J. B., Peters G. J. Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem Pharmacol. 1994 Oct 7;48(7):1327–1339. doi: 10.1016/0006-2952(94)90554-1. [DOI] [PubMed] [Google Scholar]
  20. Ruiz van Haperen V. W., Veerman G., Eriksson S., Boven E., Stegmann A. P., Hermsen M., Vermorken J. B., Pinedo H. M., Peters G. J. Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res. 1994 Aug 1;54(15):4138–4143. [PubMed] [Google Scholar]
  21. Ruiz van Haperen V. W., Veerman G., Vermorken J. B., Peters G. J. 2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol. 1993 Aug 17;46(4):762–766. doi: 10.1016/0006-2952(93)90566-f. [DOI] [PubMed] [Google Scholar]
  22. Scanlon K. J., Kashani-Sabet M., Tone T., Funato T. Cisplatin resistance in human cancers. Pharmacol Ther. 1991 Dec;52(3):385–406. doi: 10.1016/0163-7258(91)90033-i. [DOI] [PubMed] [Google Scholar]
  23. Steward W. P., Dunlop D. J., Dabouis G., Lacroix H., Talbot D. Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results. Semin Oncol. 1996 Oct;23(5 Suppl 10):43–47. [PubMed] [Google Scholar]
  24. Terheggen P. M., Emondt J. Y., Floot B. G., Dijkman R., Schrier P. I., den Engelse L., Begg A. C. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum. Cancer Res. 1990 Jun 15;50(12):3556–3561. [PubMed] [Google Scholar]
  25. Vermorken J. B., van der Vijgh W. J., Klein I., Gall H. E., van Groeningen C. J., Hart G. A., Pinedo H. M. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther. 1986 Feb;39(2):136–144. doi: 10.1038/clpt.1986.24. [DOI] [PubMed] [Google Scholar]
  26. van Haperen V. W., Veerman G., Vermorken J. B., Pinedo H. M., Peters G. Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine. Biochem Pharmacol. 1996 Apr 12;51(7):911–918. doi: 10.1016/0006-2952(95)02402-6. [DOI] [PubMed] [Google Scholar]
  27. van Moorsel CJ, Peters GJ, Pinedo HM. Gemcitabine: Future Prospects of Single-Agent and Combination Studies. Oncologist. 1997;2(3):127–134. [PubMed] [Google Scholar]
  28. van der Vijgh W. J. Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet. 1991 Oct;21(4):242–261. doi: 10.2165/00003088-199121040-00002. [DOI] [PubMed] [Google Scholar]
  29. van der Wilt C. L., Smid K., Aherne G. W., Noordhuis P., Peters G. J. Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells. Eur J Cancer. 1997 Mar;33(3):471–478. doi: 10.1016/s0959-8049(97)89024-7. [DOI] [PubMed] [Google Scholar]
  30. van der Wilt C. L., Visser G. W., Braakhuis B. J., Wedzinga R., Noordhuis P., Smid K., Peters G. J. In vitro antitumour activity of cis- and trans-5-fluoro-5,6-dihydro-6-alkoxy-uracils; effects on thymidylate synthesis. Br J Cancer. 1993 Oct;68(4):702–707. doi: 10.1038/bjc.1993.413. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES